ArticleBMC cardiovascular disorders2026
Association of routine inflammatory biomarkers and derived indices with heart failure progression in preserved ejection fraction.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure with preserved ejection fraction (HFpEF) is driven by systemic inflammation, yet the prognostic utility of routine inflammatory biomarkers and derived indices remains underexplored. This study evaluates the association of high-sensitivity C-reactive protein (hsCRP), albumin, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), and pan-immune-inflammatory value (PIV) with HFpEF outcomes.
methodsIn a retrospective cohort of 312 HFpEF patients (mean age 72.6 ± 10.1 years, 54% female) from Tokat Gaziosmanpasa University Hospital (2018-2022), we analyzed baseline and longitudinal trends in biomarkers using electronic health records. Multivariable Cox models assessed associations with heart failure hospitalization and all-cause mortality, with subgroup analyses in obese, diabetic, and high-inflammatory (hsCRP > 3 mg/L) patients. A composite inflammatory score (hsCRP, SII, PIV) was evaluated for predictive accuracy.
resultsOver a median 22-month follow-up, 82 patients (26.3%) experienced hospitalization, and 48 (15.4%) died. Baseline hsCRP (HR 1.09 per mg/L, p = 0.011), NLR (HR 1.14 per unit, p = 0.002), and lower albumin (HR 0.68 per g/dL, p = 0.020) predicted hospitalization, as did longitudinal increases in hsCRP and NLR (p < 0.001). SII and PIV were significant in diabetic and high-inflammatory subgroups, respectively. The composite score improved hospitalization prediction (AUC 0.78 vs. 0.71 for hsCRP, p = 0.042).
conclusionRoutine inflammatory biomarkers, particularly their longitudinal trends, predict HFpEF progression. The composite score offers a practical tool for risk stratification, guiding personalized management in community settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.